Amphion owns 29.1% of Motif Bio, an AIM-listed group that has a new antibiotic Iclaprim just about to start a phase III trial.
Shares in () jumped more than 20% as one of main investments announced a listing on Nasdaq.
Amphion owns 29.1% of Motif Bio (), an AIM-listed group that has a new antibiotic Iclaprim just about to start a phase III trial.
It noted the plans but gave no indication of how its stake will be affected. Motif Bio is aiming to raise US$60mln, which compares to Amphion’s current market value of £7.2mln (US$9.6mln).
The company announced today it would draw down US$750,000 of a loan facility that can be converted into shares at prices of 6.5p and 8p.
Amphion shares today rose 20% to 3.75p
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Amphion Innovations PLC named herein, including the promotion by the Company of Amphion Innovations PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE